BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17690595)

  • 1. Open-label escitalopram treatment for pathological skin picking.
    Keuthen NJ; Jameson M; Loh R; Deckersbach T; Wilhelm S; Dougherty DD
    Int Clin Psychopharmacol; 2007 Sep; 22(5):268-74. PubMed ID: 17690595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind trial of fluoxetine in pathologic skin picking.
    Simeon D; Stein DJ; Gross S; Islam N; Schmeidler J; Hollander E
    J Clin Psychiatry; 1997 Aug; 58(8):341-7. PubMed ID: 9515971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.
    Grant JE; Chamberlain SR; Redden SA; Leppink EW; Odlaug BL; Kim SW
    JAMA Psychiatry; 2016 May; 73(5):490-6. PubMed ID: 27007062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder.
    Dougherty DD; Jameson M; Deckersbach T; Loh R; Thompson-Hollands J; Jenike M; Keuthen NJ
    Int Clin Psychopharmacol; 2009 Nov; 24(6):306-11. PubMed ID: 19730388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine.
    O'Sullivan RL; Phillips KA; Keuthen NJ; Wilhelm S
    Psychosomatics; 1999; 40(1):79-81. PubMed ID: 9989126
    [No Abstract]   [Full Text] [Related]  

  • 7. Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase.
    Dell'Osso B; Hadley S; Allen A; Baker B; Chaplin WF; Hollander E
    J Clin Psychiatry; 2008 Mar; 69(3):452-6. PubMed ID: 18312057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-injurious skin picking: clinical characteristics and comorbidity.
    Wilhelm S; Keuthen NJ; Deckersbach T; Engelhard IM; Forker AE; Baer L; O'Sullivan RL; Jenike MA
    J Clin Psychiatry; 1999 Jul; 60(7):454-9. PubMed ID: 10453800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
    Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
    Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging skin-picking behaviour after serotonin reuptake inhibitor-treatment in patients with obsessive-compulsive disorder: possible mechanisms and implications for clinical care.
    Denys D; van Megen HJ; Westenberg HG
    J Psychopharmacol; 2003 Mar; 17(1):127-9. PubMed ID: 12680750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine in pathologic skin-picking: open-label and double-blind results.
    Bloch MR; Elliott M; Thompson H; Koran LM
    Psychosomatics; 2001; 42(4):314-9. PubMed ID: 11496020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escitalopram in the treatment of obsessive-compulsive disorder.
    Zohar J
    Expert Rev Neurother; 2008 Mar; 8(3):339-49. PubMed ID: 18345966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
    Pallanti S; Quercioli L; Koran LM
    J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
    Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
    J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.
    Mohamed S; Osatuke K; Aslam M; Kasckow J
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):201-9. PubMed ID: 17062320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.
    Koponen H; Lepola U; Leinonen E; Jokinen R; Penttinen J; Turtonen J
    Acta Psychiatr Scand; 1997 Nov; 96(5):343-6. PubMed ID: 9395151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trichotillomania and skin-picking: a phenomenological comparison.
    Lochner C; Simeon D; Niehaus DJ; Stein DJ
    Depress Anxiety; 2002; 15(2):83-6. PubMed ID: 11891999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation.
    Grant JE; Potenza MN
    Int Clin Psychopharmacol; 2006 Jul; 21(4):203-9. PubMed ID: 16687991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram prevents relapse of obsessive-compulsive disorder.
    Fineberg NA; Tonnoir B; Lemming O; Stein DJ
    Eur Neuropsychopharmacol; 2007; 17(6-7):430-9. PubMed ID: 17240120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.
    Dougherty DD; Corse AK; Chou T; Duffy A; Arulpragasam AR; Deckersbach T; Jenike MA; Keuthen NJ
    Int J Neuropsychopharmacol; 2015; 18(2):. PubMed ID: 25637377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.